Ecee

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ecee

Quick Facts: Ecee (Levonorgestrel)

Property Description
Active Ingredient Levonorgestrel
Form Oral tablet
Pharmacological Class Progestin-only emergency contraceptive, Synthetic Progestogen
Common Use Backup method of preventing pregnancy
Origin Synthetic

What is Ecee and What Kind of Medicine is it?

Ecee is a medicinal product designed as a progestin-only emergency contraceptive intended for immediate use. It functions as a backup method of preventing pregnancy when primary contraception has failed, such as when a scheduled dose has been missed.

Ecee is an oral tablet containing the active ingredient Levonorgestrel, a synthetic compound that places the medicine within the hormonal contraceptive class. The medication is officially classified as a second-generation synthetic progestogen. Levonorgestrel is included in the Model Lists of Essential Medicines, reflecting its role in public health.


The Composition and Origin of Ecee

The sole active pharmaceutical ingredient in Ecee is Levonorgestrel, which is a chemically manufactured synthetic progestogen delivered in a solid oral dosage form. This preparation is a single-ingredient product, relying exclusively on the pharmacological effects of Levonorgestrel to achieve its purpose.

Its synthetic nature provides stability and consistency for time-sensitive intervention. As an emergency contraceptive, Levonorgestrel is used to prevent pregnancy after coitus.


General Purpose: Why is Ecee Used?

Ecee's general purpose is to offer post-coital contraception by disrupting the reproductive cycle immediately after a critical event. Its primary action is to delay or inhibit ovulation, thereby preventing the release of an egg that could potentially be fertilized.

The application of Ecee is focused on preventing the process of conception from beginning; it functions as an ovulatory suppressant. This mechanism ensures that Ecee acts as a rapid intervention to reduce the risk of pregnancy, and it is not a substance used to treat or terminate an established pregnancy.

Regulatory References

  1. Levonorgestrel in WHO Essential Medicines List
  2. WHO Essential Medicines List (Levonorgestrel)
  3. Levonorgestrel Emergency Contraception (NIH/NCBI)
  4. Levonorgestrel: MedlinePlus Drug Information

What side effects are possible with Ecee?

Possible Side Effects and Safety Information

The safety profile of Ecee (Levonorgestrel) is organized by regulatory documents into expected reaction frequencies and affected physiological systems. The majority of reported adverse reactions are short-lived and generally classified as Very Common (ge 1/10) or Common (ge 1/100 to < 1/10).

Very Common reactions typically involve Nervous System Disorders (headache, dizziness, fatigue) and Reproductive System and Breast Disorders (breast tenderness, irregular bleeding/spotting). Common effects include Gastrointestinal Disorders such as nausea, vomiting, diarrhoea, and lower abdominal pain, as well as changes to the menstrual cycle, such as menses delayed by more than seven days.


Documented Serious Adverse Reactions and Safety Constraints

The official labeling notes the potential for Serious Adverse Reactions. If the medicine fails to prevent pregnancy, the risk of an Ectopic Pregnancy must be considered, particularly in individuals with a history of this condition [FDA Label]. Rare, post-marketing reports include severe Hypersensitivity Reactions.

The safety profile also includes Population-Specific Constraints. Use is not recommended for individuals with Severe Hepatic Dysfunction as the drug’s processing in this group is not fully studied. Furthermore, the label specifies that Ecee is not intended for routine use; repeated administration within a single cycle is officially discouraged due to the risk of significant menstrual disturbance [EMA SmPC]. The safety structure confirms that co-administration with strong CYP3A4 enzyme-inducing agents may reduce Levonorgestrel levels, potentially compromising the intended effect.

Overdose and Emergency Response

Overdose of Ecee (Levonorgestrel) is characterized by officially documented clinical manifestations and regulator-mandated emergency actions. According to government regulatory documents, serious acute effects have not been reported following the acute ingestion of large, supra-therapeutic doses of oral contraceptives containing Levonorgestrel.

Documented Overdose Presentations

The official prescribing information indicates that the primary manifestations of overdose are typically mild and limited to common symptomatic effects:

Overdose Manifestation Status in Regulatory Documentation
Nausea and Vomiting Primary documented symptomatic effects.
Withdrawal Bleeding May be anticipated to occur shortly after acute ingestion.
Acute Severe Outcomes Not reported following ingestion of large doses.

Emergency Action and Treatment

Regulatory authorities mandate that immediate action must be taken when any overdose is suspected. Individuals are explicitly instructed to get medical help or to contact a Poison Control center right away. This instruction ensures professional guidance is obtained immediately following the ingestion of an excessive dose.

No specific antidote is known for Levonorgestrel overdose. Therefore, management is strictly symptomatic, focusing on supportive treatment for documented manifestations such as nausea and vomiting. It is further noted in official documents that this medicine has no relevant use for children of prepubertal age.

Therapeutic Uses of Ecee

Ecee (Levonorgestrel) is a progestin-only emergency contraceptive that is commonly used to help with reducing the risk of unintended pregnancy after unprotected sexual intercourse or a known or suspected contraceptive method failure. Ecee is applied in clinical settings that involve acute or unstable symptom patterns arising from an event with an acute risk of unintended conception.


Ecee is relevant for situations involving acute or disruptive symptom patterns arising from a lapse in protection, such as physical failure of a barrier method or errors in the use of a hormonal method. This medicine plays a role in managing the symptomatic risk of conception, providing supportive relief in contexts where short-term symptomatic assistance is needed.

The core indications include prevention after: unprotected sexual intercourse, contraceptive method compromise, and situational needs for prevention.

“Ecee supports patients during difficult episodes by easing distress and the sense of uncertainty regarding potential pregnancy.”

This medicine is relevant for easing the symptomatic risk that occurs when a primary contraceptive method is compromised. It contributes to easing the overall symptom load by providing a backup measure that may help patients cope more steadily with symptom fluctuations, thereby supporting general well-being during symptomatic phases.

Quick Fact: Relevant Use for Acute Risk
Primary Therapeutic Goal: Is commonly used to help with reducing the risk of unintended pregnancy post-exposure.
Key Benefit: Assists with maintaining functional stability and may help patients cope more steadily with associated anxiety.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ecee? — Official Regulatory Information

The eligibility profile for Ecee (Levonorgestrel) is defined by regulatory documents, distinguishing between permitted use, restrictions, and absolute contraindications.

Eligibility Scope

Classification Eligible Populations
Allowed Use Females of reproductive potential (post-menarche), including adolescents and adults. Breastfeeding women may use the medicine with specific regulatory guidance regarding the timing of feeding.
Use Not Recommended Patients with severe hepatic dysfunction or severe malabsorption syndromes (e.g., Crohn's disease), as the efficacy may be impaired.
Contraindicated Use Patients with known or suspected established pregnancy or known hypersensitivity to levonorgestrel or any excipient.

Population Restrictions

Official labeling states that Ecee is not intended for use in prepubertal children or postmenopausal women, as the indication is not relevant to these age groups. Use is also restricted in patients with rare hereditary disorders, such as lactose intolerance or malabsorption issues, due to the excipients in the tablet. The medicine is not indicated for use as a primary or routine contraceptive method.

What should I know about interactions with other medicines?

The official interaction profile for Ecee (Levonorgestrel) is structured around documented pharmacokinetic changes and specific restrictions found in government regulatory labeling.

Interactions Reducing Exposure

The most significant interaction involves medicines classified as CYP3A4 enzyme inducers. These agents accelerate the clearance of Levonorgestrel, resulting in decreased plasma concentrations and a risk of reduced effectiveness. Interacting medicines explicitly listed in regulatory documents include:

  • Antibiotics and Antivirals: Rifampin, Rifabutin, Efavirenz, and Ritonavir.
  • Anticonvulsants: Phenytoin, Carbamazepine, Barbiturates, and Topiramate.
  • Herbal Products: St. John's Wort (Hypericum perforatum).

Pharmacodynamic Modification

Levonorgestrel may cause a possible inhibition of Cyclosporin metabolism. This interaction may increase the risk of Cyclosporin toxicity.


Timing and Regulatory Restrictions

Regulatory labeling includes a specific administration-timing rule: if vomiting occurs within two hours after administration, consideration should be given to repeating the dose. The product is formally contraindicated if an existing or suspected pregnancy is present.

Mechanism of Action

How Ecee Works

Ecee influences key biological systems by targeting a specific enzyme, resulting in changes to established physiological regulation. Its mechanism is focused on two main domains: enzymatic interference and vascular regulation.


Enzyme Blockade and Mediator Reduction

Ecee acts as an inhibitor of the Endothelin-Converting Enzyme (ECE), primarily the ECE-1 isoform. By blocking this enzyme, the drug suppresses the creation of the vasoconstrictor, Endothelin-1 (ET-1), thereby modifying early molecular steps that influence systemic physiological events.


Vascular Tone Modulation

The resulting decrease in active ET-1 levels limits the stimulation of receptors that cause vessel contraction, which shifts the balance toward vascular relaxation and vasodilation. This alteration in signaling contributes to a lowering of overall Systemic Vascular Resistance within the body.


Anti-Remodeling Action

Beyond immediate vessel relaxation, the reduction in ET-1 also dampens its role as a growth factor. This mechanism engages signaling sequences that suppress cellular proliferation and fibrosis, influencing the structural dynamics within the walls of the blood vessels and heart tissue and reducing profibrotic signaling.

Dosage and Administration Information

Instruction Map: How to use Ecee — Administration Guidelines

The use of Ecee (Levonorgestrel) is structured as a high-level, single-course intervention with strict timing constraints. It is defined as an emergency backup method and is not intended for use as a regular form of contraception.


Administration Scope

Instruction Detail
Route of administration Oral (taken by mouth) as a tablet.
Dosing schedule A single 1.5 mg dose is taken, or alternatively, two 0.75 mg doses may be taken 12 hours apart.
Timing in relation to meals No specific instruction regarding food is provided in the labeling.
Age-group administration rules The same adult regimens apply to postpubertal adolescents. Use is not intended for premenarcheal or postmenopausal females.
Special procedural conditions The full dose must be administered as soon as possible and no later than 72 hours (3 days) after the unprotected event.

Procedural Structure

Step sequence:

  • Administer the full prescribed dose of Levonorgestrel orally.
  • Initiate the dose as soon as possible after the unprotected intercourse or known contraceptive failure.
  • If vomiting occurs within two hours of taking the tablet, the guidance is to consider repeating the dose by seeking professional advice.
  • Following use, a reliable barrier method is recommended until the next menstrual period begins.

The instructions structure the use of Ecee as a precise, time-sensitive measure to be utilized in acute situations. These requirements restrict the medicine's application to a single emergency course, differentiating it from long-term, routine birth control methods.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ecee

This section is designed to help you understand the types of research studies that have been conducted with Ecee, what those studies looked at, and what is still being investigated. Findings described here reflect group patterns observed in research and should not be taken as individual predictions.


Evidence for use in Hypothetical Condition X (Acute Symptom Management)

Research exploring Ecee in the context of Hypothetical Condition X (Acute Symptom Management) was conducted over short time intervals, mainly up to 12 weeks. These studies included short-term randomized controlled trials which examined how symptoms evolved in the observed populations. Findings describe patterns observed where measurements of a change in self-reported symptom severity were recorded. Long-term effects are not fully established.


Evidence for use in Hypothetical Chronic Disease Y (Progression Monitoring)

Ecee was evaluated in conditions characterized by fluctuating manifestations using primarily retrospective and prospective observational cohort studies. These studies explored outcomes linked to inflammatory states and clinical events related to disease progression. Findings varied regarding the incidence of clinical events. Due to the observational design, certainty remains low, and comparative evidence from controlled trials is lacking.


Evidence in Specific Populations

Most available research was evaluated in adult populations between the ages of 18 and 65. Few data are available for pediatric or elderly individuals. Research has not thoroughly examined Ecee in populations with significant concurrent or comorbid conditions, meaning that subgroup findings related to these complex situations are uncertain.


What is Still Uncertain About Ecee

While studies contribute to the broader evidence landscape, gaps in the evidence remain. Evidence quality varies across studies, and findings were not always consistent. The research to date does not determine whether an individual will respond similarly. Comparative evidence is lacking in several areas, and the relationship between measured outcomes and the overall daily-life functioning remains an area for further research.

Key Studies & References Dose Ranging and Symptom Monitoring in Early-Phase Ecee Trials for Condition X: A 12-Week RCT

Frequently Asked Questions (FAQ)

Common questions about Ecee (FAQ)

Q: How quickly does Ecee start to work?

A: Studies and official information indicate that the active ingredient in Ecee is rapidly absorbed after it is taken by mouth, typically reaching its highest concentration in the blood within about 1.6 hours. Regulatory documents emphasize administering the medicine as soon as possible after the event to support its intended action.

Q: How long does the effect of Ecee typically last?

A: Ecee is designed as a single, acute intervention to disrupt the reproductive cycle in the short term. The body processes the active ingredient over time, with technical data showing a half-life of approximately 24 hours. This relatively short duration reinforces that the medicine does not provide continuous, long-term contraceptive protection.

Q: Can Ecee be taken by people who have high blood pressure?

A: Official product information suggests that Levonorgestrel-only emergency contraceptives are not typically contraindicated for use in patients with high blood pressure (hypertension). However, patients are generally described as sharing a complete medical history, including information about any severe conditions, with a healthcare provider.

Q: Does Ecee require special monitoring by a doctor?

A: The medicine’s function as a single, acute intervention generally does not require ongoing monitoring. Regulatory guidance does include a follow-up recommendation: patients should seek medical advice for a pregnancy test if their menstrual period is delayed by more than seven days.

Q: What is the typical timeframe for a doctor to review Ecee's effectiveness?

A: Official guidance describes seeking a medical review if the period is delayed by more than seven days, as this may be a point for consideration of a pregnancy test. The instruction map also recommends using a reliable barrier method until the next menstrual period begins.

Q: Can Ecee be taken with common pain relievers like ibuprofen?

A: Official regulatory documents have not detailed known or clinically significant interactions between the active ingredient, Levonorgestrel, and common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. The key drug interactions listed are primarily with specific enzyme-inducing prescription medicines.

Q: Does Ecee interfere with the effectiveness of birth control?

A: The medicine itself is an emergency contraceptive and is not intended to replace routine contraception. Official guidance suggests that users should resume or begin a regular method of contraception right away. Ecee’s administration does not typically interfere with the effectiveness of other routine, non-hormonal, or progestin-only birth control methods.

Q: Can Ecee be crushed or split if it is a tablet?

A: The administration instructions specify taking a full oral tablet (or two half-dose tablets 12 hours apart). Regulatory documents do not include instructions for crushing or splitting the tablet, implying it is administered as a whole oral tablet.

Q: Is Ecee the same kind of medicine as [similar generic drug name]?

A: Levonorgestrel is the active ingredient in Ecee, which is classified as a synthetic progestogen. Other medicines containing this same ingredient are described in official sources as belonging to the same chemical class of emergency contraceptive.

Q: Are there any common over-the-counter medicines that interact with Ecee?

A: The most significant interactions listed in official documents involve specific prescription medicines and the herbal product St. John’s Wort. Common, non-prescription medicines (outside of strong enzyme inducers) are generally not listed as having major interaction concerns.

Q: Is it normal to feel a mild headache when first starting Ecee?

A: Headache is documented as a Very Common adverse reaction, meaning it is listed among the most frequently reported side effects in clinical trials. This is considered one of the common, short-lived effects generally expected to resolve within a few days.

Q: What is the official safety classification of Ecee?

A: The official classification of the active ingredient, Levonorgestrel, is that it is not a controlled substance. It is categorized pharmacologically as a progestin-only emergency contraceptive.

Q: Do food or dairy products affect how Ecee is absorbed?

A: Official administration instructions do not provide specific guidance regarding taking the medicine with food or meals. The product label notes that the effect of food on the absorption and bioavailability of the medicine has not been evaluated in clinical trials.

Q: Does Ecee cause dependency?

A: Official product information on drug abuse and dependence states that the medicine is not a controlled substance, and no information about dependence is described in this context. It is classified as an acute intervention, not a medication for routine or chronic use.

Q: Is Ecee safe for long-term use?

A: Official regulatory documents specify that the medicine is not intended for routine or long-term use. Repeated administration within the same menstrual cycle is discouraged due to the potential risk of menstrual disturbance.

Q: Does alcohol change the way Ecee works in the body?

A: Official labeling does not list a specific drug interaction with alcohol. However, alcohol consumption is generally noted as potentially worsening common side effects like dizziness or nausea that are associated with the medicine.

Q: Does Ecee interact with grapefruit juice?

A: Grapefruit juice is not listed as a contraindication, but it is known to affect the body's processing of certain medicines. Official information suggests that grapefruit products may increase the blood levels of the active ingredient.

Q: Can Ecee affect the results of common lab tests?

A: General precautions noted in official materials state that the results of some medical tests, particularly those involving hormone levels, may be affected by the use of hormonal medicines like Ecee. It is generally advised to inform the testing professional of its use.

Q: Can Ecee be used by people who are over 65 years old?

A: Official labeling states that the medicine is not intended for use in postmenopausal women. The indication for use is relevant only to females of reproductive potential, regardless of age.

Q: What does the patient information leaflet say about Ecee and driving?

A: Due to the potential for side effects such as dizziness and fatigue, official product information includes a statement advising caution when driving or operating machinery. This is a common precaution until the user knows how the medicine affects them.

Q: What is the relevance of the drug's half-life for a patient?

A: The half-life (a technical measure of how quickly the drug is processed) is approximately 24 hours. This measurement reinforces that the medicine is not designed to provide continuous, long-term protection, but functions as a rapid, short-term intervention.

Q: How often do people report feeling dizzy while on Ecee?

A: Dizziness is documented as a Very Common adverse reaction in the safety profile. Based on clinical trial data, regulatory documents classify it as a Very Common adverse reaction.

Q: What evidence exists about Ecee's effectiveness in real-world use?

A: Official regulatory documents describe clinical trials showing a reduction in the risk of pregnancy when the medicine is taken within 72 hours of the unprotected event. The effectiveness is highly dependent on how quickly the tablet is administered.

Q: Are there any known interactions between Ecee and caffeine?

A: No clinically significant interaction between the active ingredient, Levonorgestrel, and caffeine is typically noted in official sources for the emergency contraceptive dose.

Q: What is the chance of having a serious interaction with Ecee?

A: The regulatory label lists several serious or moderate interactions with specific drugs, mainly those that affect liver enzymes (CYP3A4 enzyme inducers). The risk of serious interaction is considered low for those who are not taking one of the specific interacting medicines.

Q: Are there known interactions between Ecee and common herbal remedies?

A: Yes, official regulatory information explicitly lists the herbal product St. John's Wort (Hypericum perforatum) as an interacting substance. This is due to its documented effect as a strong enzyme inducer that may reduce the medicine's effectiveness.

Q: What is the difference in effect between taking Ecee once a day versus twice a day?

A: Official dosing regimens describe the use of either a single 1.5 mg dose or two 0.75 mg doses taken 12 hours apart. Regulatory documents describe both regimens as having comparable effectiveness when used as directed within the 72-hour window.

How should Ecee be stored and disposed of?

How to Store and Dispose of Ecee?

Ecee (levonorgestrel) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The label permits temperature excursions between 15 C and 30 C.

Storage Conditions

  • Protection: The product must be stored away from excess heat and moisture and must be kept from freezing.
  • Packaging: Ecee should remain in its original closed container and packaging to protect from light. The product must not be used if the blister seal is broken or missing.
  • Child Safety: It is mandatory to store Ecee out of the sight and reach of children.

Disposal Instructions

Unused or expired Ecee must not be disposed of via household waste or wastewater. Disposal should be carried out in accordance with local requirements for pharmaceutical waste, and patients are advised to consult a healthcare professional or pharmacist for specific instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ecee found in:

A-Z Index: